CreamEqalix, Inc. is a private, pre-clinical – stage, pre-revenue regenerative medicine device company that is developing a plant-based skin substitute wound dressing, OmegaSkin™ wound dressing (“OmegaSkin™”), to replace skin substitutes made from human or animal sources in the multibillion dollar global wound care market.
We have animal data showing that wounds dressed with OmegaSkin™ result in about 1/3 less scarring, strikingly earlier and greater new blood vessel formation (necessary for healing in the early stages), restoration of epithelial cells (the last layer of skin to heal) and collagen reorganization (a sign of healing), and actual restoration of skin appendages such as hair follicles and sweat glands, compared to control dressings.
By switching the source from human or animal tissues to soy, an inexpensive and ubiquitous crop, and electrospinning (a well-characterized manufacturing process borrowed from the textile industry – essentially 3D printing), we project unit costs roughly an order of magnitude lower than currently marketed products.
This technology platform was invented by Peter Lelkes, Ph.D., Director of the Temple University Institute for Regenerative Medicine and Engineering in Philadelphia. A U.S. patent covering the technology was issued in July 2014.
Our mission is to extend access to culturally sensitive advanced wound care at disruptive, affordable prices for many millions more patients in the U.S. and around the globe while returning a double digit multiple to investors. .